Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 1Genitourinary 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × Technetium Tc 99m Sestamibi × Thoracic × Clear all
NCT00560495 2022-10-03

Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 1 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡